Business Wire

MindMaze Drives Future of Upper-Limb Neural Recovery with a First-in-Class Smart Peripheral for Hand Dexterity Assessment and Training

Share

MindMaze, a global pioneer in the development of AI-driven digital neurotherapeutics, is proud to announce the US and EU launch of Izar ®1, a first-of-its-kind, FDA-listed and CE-marked smart peripheral for patients with impairment in hand motor function. Izar is designed to fill a critical gap in neurological care today and aims to be the most effective hand dexterity and strength treatment in a wide range of neurological conditions. This proprietary peripheral is a significant step forward in MindMaze’s efforts to deliver more effective patient care through combinations of smart peripherals with its growing portfolio of Digital Care and Digital Medicine solutions. Izar is part of a comprehensive omnisite approach to the treatment and maintenance of neurological diseases, including Stroke, Parkinson’s disease, Alzheimer’s disease, and Traumatic Brain Injury (TBI), among others.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230214005567/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Izar device: hand therapy solution (Photo: Business Wire)

Our hands are vital for everyday life – from buttoning up a shirt, to eating, typing, or driving a car – hands are essential for personal and economic independence. Impaired hand function is one of the most common disabilities after stroke with paralysis of the hand and upper limb occurring in up to 87% of all stroke survivors. Not surprisingly, patients rate hand recovery as one of the most important factors associated with their improved quality of life and independence. Yet today hands remain incredibly challenging to treat under the current standard of care given the inherent limitations in time, resources and technology. Izar allows clinics to finally address the unmet or underserved need of hand recovery through new in-clinic or remotely supervised self-training programs at home, increasing the dose and quality of training.

Izar is a hyper-sensitive controller built from the ground-up to train and assess both dexterity and strength, through capture of the fine grasp forces and wrist movements required to carry out activities of daily living. Izar can detect sub-newton level patient finger and hand forces, enabling treatment in the most impaired patient populations. This simple and highly portable controller is accompanied by proprietary and engaging gaming content that allows patients to self-train, either in-clinic, at bedside, or in the comfort of their home, dramatically enhancing and expanding training opportunities.

“It is very exciting to have a device for the hand that has the versatility of Izar. It can serve as a controller during reach-to-grasp movements, as a trainer of grip force gradation, and as an assessor of dexterity,” said Professor John Krakauer, M.D., Ph.D. and MindMaze’s Chief Medical Director. “The device is also highly portable, so it can be used across the continuum of care, which is important as the upper limb, and the hand in particular, gets relatively neglected in neurorehabilitation.”

Leading global centers such as Shirley Ryan Ability Lab in the US, University College London in the United Kingdom, and The University of Aukland in New Zealand are already actively using Izar in pioneering clinical research. Izar was subjected to rigorous pre-launch testing across nine sites and delivered over 250 hours of active supervised and self-training therapy time in 250 patients, receiving unanimously positive feedback.

“With Izar I felt my hand again for the first time, I could even actively move it a bit and I saw that on the screen. It gave me a lot of hope,” said a Berit H., a patient from the P.A.N. Zentrum Centre in Germany. Julia Knape, a therapist from the same program added: “Our clients were actually surprised to see that they still had hand-finger functions. Through the visual feedback of even the smallest functions, they were more motivated for the therapy.”

Izar is available today in the US as well as European countries including France, Switzerland and Germany with content that enables training of dexterous grasp, pinch and grip. Future software content will unlock training content for wrist, bilateral movements, combination movements of the upper-limb and hand, as well as dexterity assessments for hand and wrist.

1Izar is a trademark of MindMaze Group SA, registered in the European Union and in Switzerland.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

pr@mindmaze.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye